News & Trends - MedTech & Diagnostics
Patient voice amplifies the value of medtech, strengthening launch of new report at Parliament House
MedTech & Diagnostics News: Australian patients could benefit from ground-breaking medical technologies sooner if the government implements reforms that were recommended by a House of Representatives inquiry over a year ago.
Ian Burgess, CEO of Medical Technology Association of Australia (MTAA) and Eden, an inspiring 17 year old, joined Health Industry Hub to discuss the transformative power of medtech. The interview highlighted the release of The Value of MedTech report, being launched at Parliament House tonight, that quantifies the substantial value that the medtech sector brings to Australia’s health system, economy, and most importantly, to patients.
“We wanted to provide an authoritative report that quantifies the enormous value that medtech provides to Australia,” Mr Burgess explained. “The report outlines and quantifies the contributions that med tech makes to our economy, health system, and patients every day. It also emphasises the opportunities to maximise future benefits and strengthen our health system and economy while providing great outcomes for patients.”
The conversation then shifted to Eden, who courageously shared his personal story and the decision to undergo surgery. Eden vividly described the challenges he faced due to severe pain from a rare spinal condition, impacting his daily activities and enjoyment of life as a teenager. After the recovery period, Eden’s life was completely transformed. He now experiences no pain, participates in powerlifting and mountain biking, and leads an active, pain-free lifestyle.
The interview then delved into the barriers identified in the report that pose challenges to the future growth of the medtech sector. Mr Burgess stressed the urgency of addressing these issues to prevent Australians from waiting longer than necessary for life-saving and life-changing technology. He called for a cultural shift from viewing healthcare as a short-term cost to recognising it as a long-term investment.
The MTAA is urging policymakers to recognise the broader value that medtech provides to patients and the economy and to ensure that assessment and approval processes align with this recognition.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals
Roche’s immunotherapy drug shows promising results for Australian patients with rare blood cancer
Pharma News: Roche’s immunotherapy drug has shown high response rates in patients with a rare form of blood cancer that […]
MoreNews & Trends - Pharmaceuticals
Government seals deal with industry for rare cancer therapy
Pharma News: Australian children and young adults diagnosed with high-risk neuroblastoma will continue to receive free access to a promising, […]
MoreNews & Trends - MedTech & Diagnostics
Abbott showcases leadless pacemaker system to local stakeholders
MedTech & Diagnostics News: Leadless pacemakers are promising alternatives to transvenous pacing. Abbott hosted a stakeholder event at the recent […]
MoreNews & Trends - Pharmaceuticals
Australian scientists pivotal in new drug class from BMS
Pharma News: The first new class of drug for schizophrenia in decades has been approved, offering a fresh approach by […]
More